Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by BidaskClub

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, BidAskClub reports.

A number of other research firms have also recently issued reports on COLL. Zacks Investment Research cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, October 11th. Needham & Company LLC cut their price target on Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. William Blair reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a report on Tuesday, September 17th. ValuEngine raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $24.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $24.57.

Shares of Collegium Pharmaceutical stock traded up $1.96 during trading on Wednesday, reaching $19.96. The company’s stock had a trading volume of 1,220,900 shares, compared to its average volume of 378,932. The stock has a 50-day moving average price of $12.16 and a two-hundred day moving average price of $12.08. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23. Collegium Pharmaceutical has a one year low of $10.01 and a one year high of $19.99. The stock has a market capitalization of $459.95 million, a P/E ratio of -16.77 and a beta of 0.52.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The business had revenue of $72.94 million during the quarter, compared to the consensus estimate of $74.32 million. During the same period in the prior year, the firm earned ($0.50) earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post -0.51 EPS for the current fiscal year.

In other Collegium Pharmaceutical news, Director David Hirsch sold 22,106 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $11.65, for a total transaction of $257,534.90. Following the completion of the sale, the director now directly owns 64,223 shares of the company’s stock, valued at approximately $748,197.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph Ciaffoni sold 64,821 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $18.77, for a total value of $1,216,690.17. Following the sale, the chief executive officer now directly owns 242,276 shares of the company’s stock, valued at $4,547,520.52. The disclosure for this sale can be found here. Insiders own 8.08% of the company’s stock.

Large investors have recently made changes to their positions in the business. First Quadrant L P CA increased its stake in shares of Collegium Pharmaceutical by 87.2% in the 2nd quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock valued at $59,000 after acquiring an additional 2,089 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Collegium Pharmaceutical by 33.0% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 6,041 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 1,500 shares during the last quarter. Meeder Asset Management Inc. increased its stake in shares of Collegium Pharmaceutical by 1,299.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,495 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 7,888 shares during the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at about $98,000. Finally, Paradigm Capital Management Inc. NY bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $131,000. 92.17% of the stock is owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Article: What is Elliott Wave theory?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.